Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Fuji
US Army
AstraZeneca
Cantor Fitzgerald
Healthtrust
Accenture
Citi

Generated: February 16, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HYDROCHLOROTHIAZIDE

« Back to Dashboard

Clinical Trials for Hydrochlorothiazide

Trial ID Title Status Sponsor Phase Summary
NCT00000525 Diuretics, Hypertension, and Arrhythmias Clinical Trial Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 To determine whether hypertensive patients with ECG abnormalities and receiving hydrochlorothiazide diuretics were at increased risk of sudden death.
NCT00000525 Diuretics, Hypertension, and Arrhythmias Clinical Trial Completed University of California, San Francisco Phase 3 To determine whether hypertensive patients with ECG abnormalities and receiving hydrochlorothiazide diuretics were at increased risk of sudden death.
NCT00005520 Genetic Epidemiology of Responses to Antihypertensives Completed National Heart, Lung, and Blood Institute (NHLBI) N/A To determine whether measured variation in genes coding for components of vasoconstriction and volume regulating systems predict interindividual differences in blood pressure response to therapy with a thiazide diuretic, hydrochlorothiazide, or an angiotensin II receptor blocker, candesartan, in hypertensive African-Americans (N=300 treated with each drug) and in hypertensive European Americans (N=300 treated with each drug).
NCT00005520 Genetic Epidemiology of Responses to Antihypertensives Completed Mayo Clinic N/A To determine whether measured variation in genes coding for components of vasoconstriction and volume regulating systems predict interindividual differences in blood pressure response to therapy with a thiazide diuretic, hydrochlorothiazide, or an angiotensin II receptor blocker, candesartan, in hypertensive African-Americans (N=300 treated with each drug) and in hypertensive European Americans (N=300 treated with each drug).
NCT00007592 Hypertension Screening and Treatment Program Completed VA Office of Research and Development N/A Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00089713 Systolic Pressure Efficacy and Safety Trial of Alagebrium (SPECTRA) Terminated Synvista Therapeutics, Inc Phase 2 This study comprises a 3- to 6-week hydrochlorothiazide run in phase, followed by a 12 week double-blind treatment phase, followed by a 2 week single-blind follow-up hydrochlorothiazide treatment phase. The combined total duration of patient participation is approximately 17-20 weeks. Four double-blind treatment groups approximately equal in size (98) will comprise the study population: placebo or various alagebrium dose groups (10, 50, or 150 mg/day).
NCT00095394 Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension Completed Sanofi Phase 3 The purpose of this clinical research is to learn if severe hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition, the study will also evaluate the safety and tolerability of the drugs.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Hydrochlorothiazide

Condition Name

Condition Name for Hydrochlorothiazide
Intervention Trials
Hypertension 194
Healthy 34
Essential Hypertension 28
Diabetes Mellitus, Type 2 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Hydrochlorothiazide
Intervention Trials
Hypertension 202
Diabetes Mellitus 16
Diabetes Mellitus, Type 2 13
Cardiovascular Diseases 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Hydrochlorothiazide

Trials by Country

Trials by Country for Hydrochlorothiazide
Location Trials
United States 613
Germany 56
Japan 40
Canada 40
Netherlands 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Hydrochlorothiazide
Location Trials
Texas 30
New Jersey 30
Florida 27
California 26
North Carolina 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Hydrochlorothiazide

Clinical Trial Phase

Clinical Trial Phase for Hydrochlorothiazide
Clinical Trial Phase Trials
Phase 4 109
Phase 3 93
Phase 2/Phase 3 2
[disabled in preview] 66
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Hydrochlorothiazide
Clinical Trial Phase Trials
Completed 250
Recruiting 22
Terminated 15
[disabled in preview] 33
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Hydrochlorothiazide

Sponsor Name

Sponsor Name for Hydrochlorothiazide
Sponsor Trials
Novartis 48
Boehringer Ingelheim 36
Merck Sharp & Dohme Corp. 16
[disabled in preview] 41
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Hydrochlorothiazide
Sponsor Trials
Industry 242
Other 163
NIH 10
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Citi
QuintilesIMS
Julphar
Cantor Fitzgerald
Boehringer Ingelheim
Cerilliant
Baxter
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.